AUA 2021 – SEER Shows Oncotype DX Genomic Prostate Score® Test Helps Guide Treatment Decisions

Dr. Scarlett Gomez, Professor, Department of Epidemiology and Biostatistics, UCSF; Co-Leader, Cancer Control Program, UCSF Helen Diller Family Comprehensive Cancer Center discusses the Surveillance, Epidemiology, and End Results (SEER) registry analysis in which she was an investigator that reinforced the role of Exact Sciences’ Oncotype DX Genomic Prostate Score ® Test in helping guide treatment decisions in men with localized prostate cancer. This data was presented at the 2021 American Urological Association’s Annual Meeting. 

Dr. Scarlett Lin Gomez, MPH, PhD, is a professor in the Department of Epidemiology and Biostatistics at UCSF and Co-Leader of the Cancer Control Program, UCSF Helen Diller Family Comprehensive Cancer Center. She is also an epidemiologist with research interests in the role of social determinants of health, including race/ethnicity, socioeconomic status, gender, immigration status, sociocultural factors, and neighborhood contextual characteristics, on health outcomes. She is also Director of the Greater Bay Area Cancer Registry, a part of the California Cancer Registry and the NCI Surveillance Epidemiology End Results (SEER) Program. She has contributed surveillance data regarding cancer incidence and outcome patterns and trends for distinct Asian American, Native Hawaiian, and Pacific Islander and Hispanic ethnic groups, as well as cancer patterns by nativity status and neighborhood characteristics. She developed the California Neighborhoods Data System, a compilation of small-area level data on social and built environment characteristics, and has used these data in more than a dozen funded studies to evaluate the impact of social and built neighborhood environment factors on disease outcomes.